TargED closes seed investment for the development of Microlyse – a next-generation thrombolytic clot-busting drug

Dutch life sciences VC BioGeneration Ventures led TargED’s €21.5 million Series A extension Proceeds will accelerate clinical...

- TGD001 was well tolerated with no dose-limiting toxicities across all dose cohorts, exhibiting potent thrombolytic activity -...

Financing co-led by Kurma Partners and Curie Capital, includes strong line-up of European investors  Matthew Baker appointed as...

 TargED Biopharmaceuticals B.V., a clinical-stage biotechnology company developing next-generation targeted treatments for...

Phase I trial data in rheumatoid arthritis patients demonstrates favorable safety, encouraging clinical activity, and robust...

Quickborn, Germany and Eindhoven, Netherlands – September 24, 2025 - Mammotome, a globally recognized leader in breast care, and...